文献速递糖尿病

真实临床实践中SGLT2抑制剂与肾脏结局的关联:CVD-REAL 3多国观察性队列研究

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-01-01

CVD-REAL 3是一项多国观察性队列研究,在以色列、意大利、日本、台湾和英国纳入2型糖尿病起始SGLT2抑制剂或其他降糖药且前后有eGFR测量的患者,经倾向评分1:1匹配后每组35 561例起始治疗。

核心结论

  • 在2型糖尿病真实临床实践中,起始SGLT2抑制剂与更慢的肾功能下降和更低的重大肾脏事件风险相关,临床试验肾脏获益似可外推至临床实践。

研究设计与样本

  • CVD-REAL 3为多国观察性队列研究,通过理赔、病历和国家登记在以色列、意大利、日本、台湾和英国识别SGLT2抑制剂或其他降糖药新使用者,要求起始前后180天内测量eGFR。
  • 各国构建SGLT2抑制剂起始倾向评分(含基线eGFR和起始前eGFR斜率),按1:1匹配其他降糖药起始者;匹配后每组35 561例起始治疗,来自65 231例患者。
  • 主要结局为线性混合回归模型计算的eGFR下降斜率,并评估50% eGFR下降或终末期肾病的复合结局。

临床怎么用

  • 对2型糖尿病患者,起始SGLT2抑制剂可能延缓肾功能下降并降低重大肾脏事件风险,支持在真实临床实践中应用。

局限性

  • 原文未报告局限性相关描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular and kidney outcome trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with type 2 diabetes with or without chronic kidney disease. The aim of this study was to assess whether these benefits extend to patients with type 2 diabetes treated in routine clinical practice. METHODS: CVD-REAL 3 was a multinational observational cohort study in which new users of SGLT2 inhibitors and other glucose-lowering drugs with measurements of estimated glomerular filtration rate (eGFR) before and after (within 180 days) initiation were identified via claims, medical records, and national registries in Israel, Italy, Japan, Taiwan, and the UK. Propensity scores for SGLT2 inhibitor initiation were developed in each country, with 1:1 matching with initiators of other glucose-lowering drugs. Propensity score included (in addition to other clinical and demographic variables) baseline eGFR and eGFR slope before SGLT2 inhibitor or other glucose-lowering drug initiation. The main outcome measure was rate of eGFR decline (slope) calculated with a linear mixed regression model. Differences in eGFR slope between SGLT2 inhibitors and other glucose-lowering drugs were calculated and pooled. We also assessed a composite outcome of 50% eGFR decline or end-stage kidney disease. FINDINGS: After propensity matching, there were 35 561 episodes of treatment initiation in each group, from 65 231 individual patients. Dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, tofogliflozin, and luseogliflozin accounted for 57·9%, 34·1%, 5·7%, 1·4%, 0·5%, and 0·4% of SGLT2 inhibitor initiation episodes, respectively. At baseline, 29 363 (41·3%) of 71 122 initiations were in women, mean age was 61·3 years, mean HbA1c was 72 mmol/mol (8·71%), and mean eGFR was 90·7 mL/min per 1·73 m2. During follow-up, SGLT2 inhibitor initiation was associated with reduced eGFR decline (difference in slope for SGLT2 inhibitors vs other glucose-lowering drugs 1·53 mL/min per 1·73 m2 per year, 95% CI 1·34-1·72, p<0·0001). During a mean follow-up of 14·9 months, 351 composite kidney outcomes occurred: 114 (3·0 events per 10 000 patient-years) among initiators of SGLT2 inhibitors and 237 (6·3 events per 10 000 patient-years) among initiators of other glucose-lowering drugs (hazard ratio 0·49, 95% CI 0·35-0·67; p<0·0001). These findings were consistent across countries (pheterogeneity 0·10) and prespecified subgroups. INTERPRETATION: In this large, international, real-world study of patients with type 2 diabetes, initiation of SGLT2 inhibitor therapy was associated with a slower rate of kidney function decline and lower risk of major kidney events compared with initiation of other glucose-lowering drugs. These data suggest that the benefits of SGLT2 inhibitors on kidney function identified in clinical trials seem to be largely generalisable to clinical practice. FUNDING: AstraZeneca.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020. PMID: 31862149. doi:10.1016/S2213-8587(19)30384-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。